Analysts predict seladelpar may soon be the top treatment fo...

Analysts predict seladelpar may soon be the top treatment for primary biliary cholangitis. Gilead's acquisition of CymaBay is viewed as a strategy to shift its narrative after disappointing updates on two drugs and a Trodelvy cancer drug trial.